Sugi Predict

Sugi Predict / Compounds / SCHEMBL29697124

SCHEMBL29697124

SCHEMBL29697124

N=C(N)NCCC[C@H](NC(=O)[C@@H](N)c1ccccc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ C3AR1 Q16581 6/20 0.52
▸ FNTA P49354 4/20 0.45
▸ FNTB P49356 4/20 0.45
▸ PGGT1B P53609 4/20 0.45
▸ MME P08473 1/20 0.43
▸ NPY4R P50391 5/20 0.42
▸ NPY1R P25929 3/20 0.42
▸ NPY2R P49146 2/20 0.42
▸ NPY5R Q15761 2/20 0.42
▸ GNPAT O15228 1/20 0.40
▸ FOLH1 Q04609 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30631962 0.92 C3AR1 (0.46) C3AR1FNTAFNTBPGGT1BMME
SCHEMBL14509097 0.87 NPY4R (0.44) C3AR1NPY4RNPY1RNPY2RNPY5R
SCHEMBL5966602 0.83 GNPAT (0.52) FNTAFNTBPGGT1BNPY4RNPY1R
SCHEMBL7292029 0.83 GNPAT (0.52) FNTAFNTBPGGT1BNPY4RNPY1R
SCHEMBL1711691 0.83 GNPAT (0.52) FNTAFNTBPGGT1BNPY4RNPY1R
SCHEMBL1711701 0.83 GNPAT (0.52) FNTAFNTBPGGT1BNPY4RNPY1R
SCHEMBL5966594 0.83 GNPAT (0.52) FNTAFNTBPGGT1BNPY4RNPY1R
SCHEMBL29540393 0.83 GNPAT (0.52) FNTAFNTBPGGT1BNPY4RNPY1R
SCHEMBL6801489 0.82 C3AR1 (0.61) C3AR1FNTAFNTBPGGT1BFOLH1
SCHEMBL22117583 0.81 PRSS1 (0.50) NPY4RNPY1RNPY2RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117126235-A Autophagy degradation nano-composite based on polypeptide self-assembly and preparation and application thereof 深圳湾实验室坪山生物医药研发转化中心 2023-11-28 — — CN claimed
US-20260146063-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2026-05-28 — — US disclosed
US-20260125426-A1 CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2026-05-07 — — US disclosed
US-20260070948-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO OHIO STATE INNOVATION FOUNDATION (US) 2026-03-12 — — US disclosed
US-20260070947-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-03-12 — — US disclosed
US-20260008816-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2026-01-08 — — US disclosed
US-20260008812-A1 CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-01-08 — — US disclosed
US-20260001916-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-01-01 — — US disclosed
US-12454552-B2 Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof OHIO STATE INNOVATION FOUNDATION (US) 2025-10-28 — — US disclosed
US-20250243244-A1 CYCLIC CELL PENETRATING PEPTIDES ENTRADA THERAPEUTICS, INC. 2025-07-31 — — US disclosed
US-20250011367-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF ENTRADA THERAPEUTICS, INC. 2025-01-09 — — US disclosed
US-20240368227-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES OHIO STATE INNOVATION FOUNDATION 2024-11-07 — — US disclosed
US-20240360174-A1 CELL-PENETRATING PEPTIDE SEQUENCES OHIO STATE INNOVATION FOUNDATION 2024-10-31 — — US disclosed
US-20240358845-A1 COMPOSITIONS AND METHODS FOR INTRACELLULAR THERAPEUTICS ENTRADA THERAPEUTICS, INC. 2024-10-31 — — US disclosed
US-20240245790-A1 CYCLIC CELL PENETRATING PEPTIDES ENTRADA THERAPEUTICS, INC. 2024-07-25 — — US disclosed
US-11987647-B2 Cyclic cell-penetrating peptides with one or more hydrophobic residues OHIO STATE INNOVATION FOUNDATION (US) 2024-05-21 — — US disclosed
US-20240158445-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-05-16 — — US disclosed
US-20220306693-A1 CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF OHIO STATE INNOVATION FOUNDATION 2022-09-29 — — US disclosed
US-20220177523-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF ENTRADA THERAPEUTICS, INC. 2022-06-09 — — US disclosed
US-11352394-B2 Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof OHIO STATE INNOVATION FOUNDATION (US) 2022-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011367-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF VIP, LNPEP, TAP1 C3AR1 965/4885FNTA 2303/4885FNTB 1646/4885
US-11352394-B2 Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof VIP, LNPEP, IAPP C3AR1 382/4885FNTA 2211/4885FNTB 640/4885
US-20240368227-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES VIP, LNPEP, TAP1 C3AR1 900/4885FNTA 4162/4885FNTB 2604/4885
US-20260008816-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF SLC3A2, SPPL2B, SLC7A1 C3AR1 2342/4885FNTA 1808/4885FNTB 973/4885
US-20250243244-A1 CYCLIC CELL PENETRATING PEPTIDES SLC47A1, SLC47A2, VIP C3AR1 1429/4885FNTA 4028/4885FNTB 3194/4885
US-20240245790-A1 CYCLIC CELL PENETRATING PEPTIDES SLC47A1, SLC47A2, VIP C3AR1 1429/4885FNTA 4028/4885FNTB 3194/4885
US-20260008812-A1 CELL-PENETRATING PEPTIDE COMPOUNDS SLC38A7, SLC7A1, SLC6A7 C3AR1 2359/4885FNTA 3312/4885FNTB 3266/4885
US-20260146063-A1 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF VIP, SLC7A1, SLC6A15 C3AR1 1472/4885FNTA 3178/4885FNTB 3332/4885
US-20220306693-A1 CYCLIC CELL PENETRATING PEPTIDES COMPRISING BETA-HAIRPIN MOTIFS AND METHODS OF MAKING AND USING THEREOF CHN2, TAP2, VIP C3AR1 532/4885FNTA 2079/4885FNTB 566/4885
US-20260125426-A1 CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF SLC7A1, TAP1, SLC7A5 C3AR1 2009/4885FNTA 3477/4885FNTB 3277/4885
US-20220177523-A1 CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF VIP, LNPEP, TAP1 C3AR1 965/4885FNTA 2303/4885FNTB 1646/4885
US-20260070947-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS SLC7A1, SLC38A7, SLC6A19 C3AR1 1914/4885FNTA 3255/4885FNTB 3351/4885
US-20240358845-A1 COMPOSITIONS AND METHODS FOR INTRACELLULAR THERAPEUTICS VIP, CHERP, NFATC1 C3AR1 687/4885FNTA 2629/4885FNTB 1865/4885
US-20260070948-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO SLC7A1, SLC38A7, SLC6A19 C3AR1 1315/4885FNTA 3996/4885FNTB 3938/4885
US-20260001916-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS SLC7A1, SLC38A7, SLC6A19 C3AR1 2182/4885FNTA 3078/4885FNTB 3371/4885
US-12454552-B2 Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof CHN2, TAP2, VIP C3AR1 532/4885FNTA 2079/4885FNTB 566/4885
US-20240158445-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES SLC3A2, SLC7A1, ARGLU1 C3AR1 912/4885FNTA 3874/4885FNTB 3472/4885
US-20240360174-A1 CELL-PENETRATING PEPTIDE SEQUENCES VIP, LNPEP, NGLY1 C3AR1 1163/4885FNTA 3838/4885FNTB 2772/4885
US-11987647-B2 Cyclic cell-penetrating peptides with one or more hydrophobic residues VIP, LNPEP, TAP1 C3AR1 900/4885FNTA 4162/4885FNTB 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.